Survival analysis of COVID-19 patients with comorbidities in Bekasi during 2020-2021


Abstract views 806 times


COVID-19, comorbid, survival function


Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 in patients with comorbidities progresses more rapidly to severity and frequently leads to death. Therefore, the objective of this study is to determine the length of survival and estimation of the Hazard Ratio (HR) of COVID-19 patients with comorbidities. The study design used a retrospective cohort of 3,751 samples and was analyzed using Kaplan Meier and cox regression. The survival function description shows the difference in the mean survival of COVID-19 patients without comorbid and patients with comorbidities of 78 days and 23 days, respectively, with HR of 4.4. In conclusion, comorbid COVID-19 patients possess a lower survival and a higher risk of death. 

Author Biographies

Siti Rapingah Rapingah, Universitas Islam As-Syafi'iyah Jakarta

Siti Rafingah menempuh pendidikan terakhir di Universitas Indonedia, sejak tahun 2016 menjadi dosen di Uniersitas Islam As Syafiiyah dan memiliki jabatan fungsional Asistem Ahli

Seni Wati Ruddin, Universitas Islam As-Syafiiyah Jakarta

Seniwati kelahiran Sulawesi Selatan menempuh pendidikan di Universitas Hasanuddin, sejak tahun 2017 menjadi dosen di Universitas Islam As-Syafiiyah hingga sekarang, dan memiliki jabatan fungsional sebagai asisten ahli

Shinta Silaswati Silaswati, RSUD Kota Bekasi

Shinta Silaswati kelahiran banyuwangi menempuh pendidikan terakhir di Universitas Indonesia dan sekarang menjadi dosen pengajar dengan jabatan Fungsional Asisten Ahli


Badawi, A., & Ryoo, S. G. (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. In International Journal of Infectious Diseases (Vol. 49, pp. 129–133). Elsevier B.V.

Beranda Satgas Penanganan COVID-19. (n.d.). Retrieved October 27, 2020, from

Chan, J. F. W., Kok, K. H., Zhu, Z., Chu, H., To, K. K. W., Yuan, S., & Yuen, K. Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes and Infections, 9(1), 221–236.

Diyono, B. K. (2021). Faktor Comorbid Covid-19 di Indonesia Scopyng Review. Jurnal Ilmu Kesehatan, 9(1), 51–59.

Docherty, A. B. et al. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, 369.

honghua Liu Xing Bing Xue Za Zhi. (2020). Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Pubmed, 41(2), 145–151.

Longato, E., Fadini, G. P., Sparacino, G., Gubian, L., & Di Camillo, B. (2020). Prediction of Cardiovascular Complications in Diabetes from Pharmacy Administrative Claims. Conference, Melecon. 20th IEEE Mediterranean Electrotechnical, 315–320.

Mantovani, A., Byrne, C. D., & Zheng, M. (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information. Elsevier, January.

Muhani, N., & Sari, N. (2020a). Analisis Survival pada Penderita Gagal Ginjal Kronik dengan Komorbiditas Diabetes Melitus. Media Kesehatan Masyarakat Indonesia, 16(2), 216.

Muhani, N., & Sari, N. (2020b). Kesintasan Penyakit Ginjal Kronik yang Menjalani Hemodialisis di Rumah Sakit Abdul Moeloek Lampung Tahun 2017-2018. Media Penelitian Dan Pengembangan Kesehatan, 30(3), 257–264.

Murillo-Zamora, E., & HERNANDEZ-SUAREZ, C. M. (2020). Survival in adult inpatients with COVID-19. MedRxiv.

Sari, N., & Muhani, N. (2020). Analisis Survival Pasien Hemodialisis dengan Hipertensi di Lampung Tahun 2016-2018. Media Penelitian Dan Pengembangan Kesehatan, 30(2), 89–96.

Satria, R. M. A., Tutupoho, R. V., & Chalidyanto, D. (2020). Analisis Faktor Risiko Kematian dengan Penyakit Komorbid Covid-19. Jurnal Keperawatan Silampari, 4(1), 48–55.

Smeltzer, Suzanne C. & Bare, B. G. (2017). Smeltzer & Bare Textbook of Medical Surgical Nursing. Lippincott Williams & Wilkins.M. Farrell (Ed.); 1st ed.).

Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yunihastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia, 7(1), 45.

Wang, J. J., Edin, M. L., Zeldin, D. C., Li, C., Wang, D. W., & Chen, C. (2020). Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. In Pharmacology and Therapeutics (Vol. 215, p. 107628). Elsevier Inc.

Wenjie Yang and Fuhua Yan. (2019). Patients with RT-PCR-confirmed COVID-19 and. Journal of the American Podiatric Medical Association, 96(3), 1.

World Health Organization. (2020). Situation Report-51 SITUATION IN NUMBERS total and new cases in last 24 hours. Situation Report – 51%0AData as reported by national authorities by 10 AM CET 11 March 2020 H

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020). Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91–95.

Yuliana. (2020). WELLNESS AND HEALTHY MAGAZINE Corona virus diseases (Covid. Wellness And Healthy Magazine, 2(1), 187.






Original Research Paper